비교리스트

 카트 문의
시장보고서
상품코드
1344323

암 맞춤형 의료 시장 : 제품별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Personalized Cancer Medicine Market By Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), By End User (Hospitals and clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 209 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 맞춤형 의료 시장은 2022년 1,799억 9,000만 달러로 평가되며, 2023년부터 2032년까지 CAGR 10.9%로 성장하여 2032년에는 5,072억 달러에 달할 것으로 추정됩니다.

Personalized Cancer Medicine Market-IMG1

암 맞춤형 의료 시장의 성장을 견인하는 몇 가지 중요한 요인은 암 유병률 증가와 이에 따른 효과적인 치료 옵션에 대한 수요 증가 등 몇 가지 주요 요인이 있습니다. 정밀의료는 암 치료의 유망한 접근법으로 등장하여 그 채택과 성장을 촉진하고 있습니다. 또한 인구의 고령화도 정밀의료 수요를 촉진하는 요인 중 하나입니다. 노년층은 암에 걸리기 쉬워 잠재적인 환자 풀이 더 많아집니다. 또한, 생명공학 및 유전공학의 발전으로 보다 타깃화된 맞춤형 암 치료제의 개발이 가능해지면서 시장 성장의 원동력이 되고 있습니다. 또한, 맞춤형 의약품은 임상시험에서 유망한 결과를 보여 연구개발 활동에 대한 투자 증가로 이어지고 있습니다.

또한, 제품 출시, 계약, 제휴 등 주요 시장 기업들이 채택하는 주요 전략의 증가는 예측 기간 동안 시장 성장을 더욱 촉진할 것으로 보입니다. 예를 들어, 2021년 2월 Qiagen과 생명공학 기업 Inovio Pharmaceuticals는 Inovio의 치료법을 보완하는 차세대 시퀀싱(NGS) 기술을 기반으로 한 액체 생검 기반 동반 진단 제품을 개발하기 위해 새로운 기본 제휴를 체결했습니다. 계약을 체결하고 파트너십을 연장한다고 발표했습니다.

또한, 규제 당국의 승인이 증가하고 있는 것도 시장 성장의 기회로 작용하고 있습니다. 예를 들어, 세계 제약 및 진단 분야의 선구자인 F. Hoffmann-La Roche AG는 2021년 10월 미국 식품의약국(FDA)으로부터 비소세포폐암(NSCLC)에 대한 VENTANA PD-L1(SP263) 분석을 Tecentriq의 동반진단제로 승인받았습니다. 의 동반진단제로 승인되었습니다. 이처럼 주요 업체들의 이러한 전략은 개인 맞춤형 의료 분야의 수요와 채택을 증가시켜 시장 성장에 유리한 기회를 제공할 수 있습니다.

그러나 개인 맞춤형 의료의 높은 비용이 개인 맞춤형 의료 시장의 성장을 저해하고 있습니다. 높은 진단 및 치료 비용으로 인해 경제적 여건이 좋지 않은 환자들은 접근하기 어려워 개발도상국 시장의 성장을 저해하고 있습니다. 또한, 많은 환자들이 개인 맞춤형 의료의 개념을 모르는 것도 시장 성장에 걸림돌로 작용하고 있습니다. 반면, 정부 및 비정부기구는 첨단 의료 옵션에 대한 대중의 인식을 높이고 암 맞춤 의료의 채택을 증가시킬 수 있기 때문에 예측 기간 동안 시장 확대를 촉진할 것입니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 영향요인
    • 주요 투자 기회
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
      • 암 유병률 상승
      • 이상적인 치료제에 대한 수요 증가
      • 인공지능(AI) 기반 진단 채용 증가
    • 성장 억제요인
      • 맞춤형 의료의 고비용
      • 한정된 상환과 적용 범위
    • 기회
      • 암 맞춤형 의료 연구개발 활동 증가
  • COVID-19 : 시장에 대한 영향 분석

제4장 암 맞춤형 의료 시장 : 제품별

  • 개요
  • 치료제
  • 진단

제5장 암 맞춤형 의료 시장 : 최종사용자별

  • 개요
  • 병원·클리닉
  • 기타

제6장 암 맞춤형 의료 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 일본
    • 중국
    • 호주
    • 기타 아시아태평양
  • 라틴아메리카
    • 라틴아메리카
    • 중동 및 아프리카

제7장 경쟁 상황

  • 서론
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝, 2022년

제8장 기업 개요

  • Abbott Laboratories
  • ARIEL Precision Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • General Electric
  • Aadi Bioscience, Inc.
  • Illumina, Inc.
  • Qiagen NV.
  • Novartis AG
  • Thermo Fisher Scientific Inc.
  • Bristol-Myers Squibb Company
ksm 23.09.27

According to a new report published by Allied Market Research, titled, "Personalized Cancer Medicine Market," The personalized cancer medicine market was valued at $179.99 billion in 2022, and is estimated to reach $507.2 billion by 2032, growing at a CAGR of 10.9% from 2023 to 2032.

Personalized Cancer Medicine Market - IMG1

The personalized cancer medicine market growth is being driven by several key factors such as the increase in prevalence of cancer, resulting in a greater demand for effective treatment options. Precision medicine has emerged as a promising approach for treating cancer, thus driving its adoption and growth. In addition, the aging population is another factor that drives the demand for precision medicine. The geriatric population is more prone to developing cancer, creating a larger pool of potential patients. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized cancer therapies, which are likely to drive the market growth. In addition, personalized medicines have shown promising results in clinical trials, leading to increased investment in research and development activities.

Moreover, the rise in key strategies adopted by the key market players such as product launch, agreement, and collaborations further drive the growth of the market during the forecast period. For instance, on February 2021, Qiagen and Inovio Pharmaceuticals, a biotechnology company announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

Furthermore, a rise in approvals from regulatory organizations further provides opportunity for market growth. For instance, on October 2021, F. Hoffmann-La Roche AG , a global pioneer in pharmaceuticals and diagnostics, received U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of personalized medicine arena and provide lucrative opportunity to market growth.

However, the high cost of personalized medicines hinders the growth of the personalized medicine market. High cost of diagnosis and treatment makes it inaccessible for the patients with poor financial conditions and restrains the market in developing regions. Furthermore, many patients are unaware about the concept of personalized medicines, which acts as a restrain to the market. On the other hand, government and non-government organizations create awareness about the advanced healthcare options among the population, which may increase the adoption of personalized cancer medicines, thus, driving the market expansion during the forecast period.

The personalized cancer medicine market is segmented into product, end user, and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. By end user, the market is bifurcated into hospitals & clinics and others. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).

Major key players that operate in the global personalized cancer medicine market are Abbott Laboratories, ARIEL Precision Medicine, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, Inc, Aadi Bioscience, Inc., Illumina, Inc., Qiagen, Novartis AG, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company. The key players operating in the market have adopted product approval, agreement, partnership, product launch, and collaboration as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized cancer medicine market analysis from 2022 to 2032 to identify the prevailing personalized cancer medicine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the personalized cancer medicine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global personalized cancer medicine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics

By End User

  • Hospitals and clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Aadi Bioscience, Inc.
    • Abbott Laboratories
    • ARIEL Precision Medicine, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • General Electric
    • Illumina, Inc.
    • Novartis AG
    • Qiagen NV.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cancer
      • 3.4.1.2. Increase in demand for ideal therapeutics for treatment
      • 3.4.1.3. Rise in adoption of Artificial Intelligence (AI) based diagnosis
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of personalized medicine
      • 3.4.2.2. Limited Reimbursement and coverage
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities in personalized cancer medicine
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Personalized Medicine Therapeutics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Personalized Medicine Diagnostics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PERSONALIZED CANCER MEDICINE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals and clinics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PERSONALIZED CANCER MEDICINE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Product
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Product
      • 6.2.4.1.3. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Product
      • 6.2.4.2.3. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Product
      • 6.2.4.3.3. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Product
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Product
      • 6.3.4.1.3. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Product
      • 6.3.4.2.3. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Product
      • 6.3.4.3.3. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Product
      • 6.3.4.4.3. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Product
      • 6.3.4.5.3. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Product
      • 6.3.4.6.3. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Product
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Product
      • 6.4.4.1.3. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Product
      • 6.4.4.2.3. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Product
      • 6.4.4.3.3. Market size and forecast, by End User
      • 6.4.4.4. Rest of Asia-Pacific
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Product
      • 6.4.4.4.3. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Product
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Latin America
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Product
      • 6.5.4.1.3. Market size and forecast, by End User
      • 6.5.4.2. Middle East And Africa
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Product
      • 6.5.4.2.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. ARIEL Precision Medicine, Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. General Electric
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Aadi Bioscience, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Illumina, Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Qiagen NV.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Thermo Fisher Scientific Inc.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제